Showing results (401-410 of 415) with videos related to
Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.Epilepsy & Behavior : E&B|August 7, 2019
Neuroanatomical correlates of personality traits in temporal lobe epilepsy: Findings from the Epilepsy Connectome ProjectCharlene N Rivera Bonet, Bruce Hermann, Cole J Cook, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.Blood Advances|October 20, 2020
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamideJonathan A Webster, Leo Luznik, Hua-Ling Tsai, et al.Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P Shah, Ravi Bhatia, Jessica K Altman, et al.Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.Genes and Immunity|April 24, 2009
Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicingK B Douglas, D C Windels, J Zhao, et al.Transplantation and Cellular Therapy|January 1, 2023
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 YearsJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.Pageof 42